Healthcare
Daxor Corporation(DXR)
Live Price
Offline$9.75
+3.72% today
1Y Change
+3.84%
Window
Jun 26, 2025 โ Jun 16, 2026
- Market Cap
- $50.00M
- Revenue Growth
- -76.4%
- EPS Growth
- +1572.7%
- Dividend Yield
- 0.0%
Coverage: 244 bars ยท Jun 26, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Daxor Corporation (DXR) is a Healthcare stock with a market cap of $50.00M and listed on NASDAQ. The stock last traded around $9.75 and up 3.8% across the available one-year price window (Jun 26, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of -76.4%, EPS growth of +1572.7%, a dividend yield of 0.0%. What stands out right now is revenue -76.4%, EPS +1572.7%, free cash flow -2452.6% with operating margin 6174.2% and ROIC 20.2%. Valuation already assumes a fairly strong business story at P/E 6.0 and price/sales 364.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines DXR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-76.4% vs +7.6% peer median
Operating Margin
Above sector median
+6174.2% vs +19.4% peer median
P/E
Below sector median
6.0 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2025 was reported on Mar 6, 2025, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -76.4% and EPS is at +1572.7%, with operating margin around 6174.2%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 20, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.1% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2025 Mar 6, 2025 | โ | -5.0% | +2.1% | +5.3% |
2024 Jun 29, 2024 | โ | -5.0% | +2.1% | +5.3% |
2024 May 16, 2024 | โ | -5.0% | +2.1% | +5.3% |
Benchmark Edge
DXR vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
DXR
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
DXR Max Drawdown
-39.74%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for DXR and SPY.
Company Overview
Daxor Corporation
NASDAQ Capital Market
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.
- Leadership
- Michael Richard Feldschuh
- IPO Date
- Jul 25, 1983
- Employees
- 37
- Street Address
- 109 Meco Lane
- Mailing
- Oak Ridge, TN, 37830
- Region
- Oak Ridge, TN, US
- Reporting Currency
- USD
- Investor Line
- 12123308500
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 6.0
- EV/EBITDA
- 5.7
- Price/Sales
- 364.1
- Price/Book
- 1.2
Growth
- Revenue
- -76.4%
- EPS
- +1572.7%
- Free Cash Flow
- -2452.6%
Profitability
- Gross Margin
- -57.5%
- Operating Margin
- 6174.2%
- Net Margin
- 6105.3%
- ROE
- 22.5%
- ROIC
- 20.2%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- โ
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.